Physician profile
David Mason
NPI 1649210766
$1,389.54
in general payments reported to CMS, 2019-2025
26 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $958 · 2022: $66.99 · 2023: $146 · 2024: $85.15 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $179.89 | 2021 | |
| Ferring Pharmaceuticals INC. | $174.77 | 2023-2025 | Euflexxa |
| Novo Nordisk INC | $134.10 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $119.19 | 2021 | |
| Pfizer INC. | $116.86 | 2021 | |
| Glaxosmithkline, LLC. | $87.71 | 2021 | |
| Microport Orthopedics INC | $69.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $53.64 | 2021 | |
| Amgen INC. | $48.05 | 2021-2023 | Evenity |
| Abbvie INC. | $44.95 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $42.69 | 2021 | |
| Esperion Therapeutics, INC. | $41.71 | 2021 | |
| Endo Pharmaceuticals INC. | $35.41 | 2022-2023 | Xiaflex |
| Organogenesis INC. | $32.63 | 2023 | Puraply |
| Depuy Synthes Sales INC. | $31.16 | 2025 | Monovisc |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimvie INC. | $30.33 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $21.77 | 2025 | |
| Elite Orthopedics, LLC | $21.33 | 2022 | |
| Amarin Pharma, INC. | $15.79 | 2021 | |
| Eisai INC. | $15.79 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.76 | 2021 | |
| Dexcom, INC. | $14.55 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.40 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.34 | 2021 | |
| Kerecis Limited | $4.44 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.